Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a clinical-stage biotechnology firm focused on the development of next-generation psychedelic-based treatments, has officially announced the publication of a European patent application for its novel cocaine addiction therapy. The patent, filed with the European Patent Office (EPO) under number EP 4531826, represents a critical milestone in the company’s mission to address substance use disorders with innovative, non-addictive therapeutic solutions.
A Groundbreaking Therapeutic Combination
The newly published patent centers around a proprietary formulation that combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines (NAEs), including Palmitoylethanolamide (PEA). This unique combination aims to reduce cocaine cravings and prevent relapse by targeting the neurological pathways associated with drug addiction, without negatively impacting the natural reward systems in the brain.
These studies showed that animals treated with MEAI experienced a significant reduction in drug-seeking behavior. Notably, the research also found that the treatment did not impair the animals’ motivation for natural rewards such as sucrose, indicating the therapy’s ability to specifically address compulsive drug use without affecting healthy reward mechanisms.
Enhancing Global IP Protection
The European patent publication marks a key development in Clearmind’s broader strategy to strengthen its global intellectual property portfolio. The company has filed similar patent applications in multiple jurisdictions, and this European recognition further validates its proprietary approach to addiction therapy.
“This milestone reinforces our commitment to protecting the science behind our innovative treatments,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine. “Securing intellectual property rights in major global markets is essential for supporting the future commercialization of our psychedelic-based therapeutics and ensuring continued leadership in this evolving field.”
Strategic Collaboration and Expansion
The patent is also part of an ongoing collaborative effort with SciSparc Ltd. (Nasdaq: SPRC). The partnership is exploring the combined potential of Clearmind’s MEAI compound with SciSparc’s PEA-based technologies to develop advanced treatments for a range of central nervous system (CNS) disorders. This alliance is expected to further accelerate the development of therapies targeting addiction, anxiety, depression, and other mental health conditions.
About Clearmind Medicine Inc.
Clearmind Medicine is a clinical-stage psychedelic pharmaceutical company dedicated to creating transformative solutions for pressing and under-treated health conditions. Its research and development efforts focus primarily on psychedelic-derived compounds, with the goal of advancing them through the regulatory pipeline for use as pharmaceutical treatments, functional supplements, or food-grade therapies.
The company currently manages an expansive IP portfolio comprising 19 patent families and 31 granted patents, and continues to pursue additional filings to protect its proprietary formulations and discoveries.
The publication of this European patent application represents a significant leap forward in Clearmind’s pursuit of effective therapies for cocaine addiction. By combining rigorous scientific research with strategic global partnerships and IP protection, the company continues to establish itself as a leader in the emerging field of psychedelic-based mental health treatments.